Equities research analysts forecast that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will announce sales of $6.38 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $12.50 million and the lowest estimate coming in at $250,000.00. Xenon Pharmaceuticals reported sales of $380,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 1,578.9%. The business is scheduled to issue its next quarterly earnings results on Wednesday, March 14th.

On average, analysts expect that Xenon Pharmaceuticals will report full-year sales of $6.38 million for the current fiscal year, with estimates ranging from $550,000.00 to $12.80 million. For the next financial year, analysts anticipate that the firm will post sales of $13.50 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Xenon Pharmaceuticals.

Separately, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th.

Xenon Pharmaceuticals (NASDAQ:XENE) opened at $2.45 on Friday. Xenon Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $9.95.

In other Xenon Pharmaceuticals news, Director Mohammad Azab purchased 10,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was bought at an average cost of $2.95 per share, with a total value of $29,500.00. Following the purchase, the director now directly owns 21,210 shares of the company’s stock, valued at $62,569.50. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 9.40% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of XENE. Renaissance Technologies LLC grew its stake in shares of Xenon Pharmaceuticals by 90.1% during the 1st quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after acquiring an additional 102,890 shares in the last quarter. K2 Principal Fund L.P. grew its stake in shares of Xenon Pharmaceuticals by 40.6% during the 2nd quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 47,535 shares in the last quarter. DAFNA Capital Management LLC grew its stake in shares of Xenon Pharmaceuticals by 11.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock worth $1,190,000 after acquiring an additional 38,081 shares in the last quarter. Finally, Scotia Capital Inc. grew its stake in shares of Xenon Pharmaceuticals by 36.0% during the 2nd quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 9,426 shares in the last quarter. 54.75% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.watchlistnews.com/analysts-expect-xenon-pharmaceuticals-inc-xene-will-announce-quarterly-sales-of-6-38-million/1769496.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.